IMMUNOTHERAPY VS
CHEMOTHERAPY
A detailed comparison of two fundamentally different cancer treatment approaches โ one activates your immune system, the other directly kills cancer cells.
Two Fundamentally Different Approaches
Chemotherapy directly kills cancer cells through cytotoxic mechanisms. Immunotherapy takes a different route: it removes the brakes on the immune system or engineers immune cells to recognize tumors. Both have distinct strengths, limitations, and roles in modern oncology.
โChemotherapy attacks cancer directly; immunotherapy teaches your body to fight cancer itself.โ
Immunotherapy vs Chemotherapy: Head to Head
Immunotherapy
- Activates the immune systemCheckpoint inhibitors, CAR-T, and cytokines unleash immune response.
- Durable responses possibleImmune memory can provide long-lasting protection.
- Different side effect profileImmune-related adverse events (irAEs) affect specific organs.
- Best for immunogenic tumorsMelanoma, lung, bladder, MSI-high cancers respond well.
Chemotherapy
- Directly kills cancer cellsCytotoxic agents target rapidly dividing cells.
- Faster initial responseTumor shrinkage often visible within weeks.
- Systemic side effectsHair loss, nausea, neutropenia, fatigue are common.
- Broad applicabilityEffective across most cancer types as first-line.
Detailed Comparison Table
| Factor | Immunotherapy | Chemotherapy |
|---|---|---|
| Mechanism | Immune activation | Cytotoxic cell killing |
| Response rate | 20-50% (monotherapy) | 30-70% (varies by regimen) |
| Duration of response | Often durable (years) | Typically months |
| Common side effects | irAEs: colitis, hepatitis, thyroiditis | Nausea, neutropenia, hair loss, fatigue |
| Treatment duration | 1-2 years or until progression | 4-8 cycles (3-6 months) |
| Cost per year | $100,000-$200,000 | $10,000-$60,000 |
| Combination use | Often combined with chemo | Combined with targeted/immuno |
When Is Each Approach Best?
Treatment selection depends on cancer type, biomarker status, and disease stage.
Immunotherapy First-Line
PD-L1 high (>50%) NSCLC, advanced melanoma, MSI-high tumors, renal cell carcinoma.
Chemotherapy First-Line
Most early-stage cancers, aggressive lymphomas, small cell lung cancer, ovarian cancer.
Combination (Chemo + Immuno)
NSCLC with PD-L1 <50%, triple-negative breast cancer, head and neck squamous cell carcinoma.
Sequential Use
Chemotherapy to reduce tumor burden, then immunotherapy for maintenance or consolidation.
Frequently Asked Questions
Immunotherapy vs Chemotherapy
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination โ travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Need Help Choosing the Right Treatment Approach?
Upload your medical reports and our oncology team will evaluate which treatment modality or combination may be most effective for your case.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.